{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:42:31Z","timestamp":1790959351774,"version":"4.1.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Spinocerebellar ataxia type 3\/Machado\u2013Joseph disease (SCA3\/MJD) is a progressive autosomal dominant neurodegenerative disease caused by abnormal CAG repeats in the exon 10 of<jats:italic>ATXN3<\/jats:italic>. The accumulation of the mutant ataxin-3 proteins carrying expanded polyglutamine (polyQ) leads to selective degeneration of neurons. Since the pathogenesis of SCA3 has not been fully elucidated, and no effective therapies have been identified, it is crucial to investigate the pathogenesis and seek new therapeutic strategies of SCA3. Induced pluripotent stem cells (iPSCs) can be used as the ideal cell model for the molecular pathogenesis of polyQ diseases. Abnormal CAG expansions mediated by CRISPR\/Cas9 genome engineering technologies have shown promising potential for the treatment of polyQ diseases, including SCA3. In this study, SCA3-iPSCs can be corrected by the replacement of the abnormal CAG expansions (74 CAG) with normal repeats (17 CAG) using CRISPR\/Cas9-mediated homologous recombination (HR) strategy. Besides, corrected SCA3-iPSCs retained pluripotent and normal karyotype, which can be differentiated into a neural stem cell (NSCs) and neuronal cells, and maintained electrophysiological characteristics. The expression of differentiation markers and electrophysiological characteristics were similar among the neuronal differentiation from normal control iPSCs (Ctrl-iPSCs), SCA3-iPSCs, and isogenic control SCA3-iPSCs. Furthermore, this study proved that the phenotypic abnormalities in SCA3 neurons, including aggregated IC2-polyQ protein, decreased mitochondrial membrane potential (MMP) and glutathione expressions, increased reactive oxygen species (ROS), intracellular Ca<jats:sup>2+<\/jats:sup>concentrations, and lipid peroxidase malondialdehyde (MDA) levels, all were rescued in the corrected SCA3-NCs. For the first time, this study demonstrated the feasibility of CRISPR\/Cas9-mediated HR strategy to precisely repair SCA3-iPSCs, and reverse the corresponding abnormal disease phenotypes. In addition, the importance of genetic control using CRISPR\/Cas9-mediated iPSCs for disease modeling. Our work may contribute to providing a potential ideal model for molecular mechanism research and autologous stem cell therapy of SCA3 or other polyQ diseases, and offer a good gene therapy strategy for future treatment.<\/jats:p>","DOI":"10.1038\/s41398-021-01605-2","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T07:05:27Z","timestamp":1631862327000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["CRISPR\/Cas9 mediated gene correction ameliorates abnormal phenotypes in spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cells"],"prefix":"10.1038","volume":"11","author":[{"given":"Lang","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linliu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean de Dieu","family":"Habimana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunrong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huirong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijing","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangdong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beisha","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2812-4120","authenticated-orcid":false,"given":"Hong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"1605_CR1","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1093\/brain\/awy016","volume":"141","author":"Z Chen","year":"2018","unstructured":"Chen Z, Wang P, Wang C, Peng Y, Hou X, Zhou X, et al. Updated frequency analysis of spinocerebellar ataxia in China. Brain. 2018;141:e22.","journal-title":"Brain"},{"key":"1605_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1212\/WNL.0000000000001711","volume":"85","author":"RP Maas","year":"2015","unstructured":"Maas RP, van Gaalen J, Klockgether T, van de Warrenburg BP. The preclinical stage of spinocerebellar ataxias. Neurology. 2015;85:96\u2013103.","journal-title":"Neurology"},{"key":"1605_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-019-0074-3","volume":"5","author":"T Klockgether","year":"2019","unstructured":"Klockgether T, Mariotti C, Paulson HL. Spinocerebellar ataxia. Nat Rev Dis Prim. 2019;5:24.","journal-title":"Nat Rev Dis Prim"},{"key":"1605_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.pneurobio.2011.11.006","volume":"97","author":"C Costa Mdo","year":"2012","unstructured":"Costa Mdo C, Paulson HL. Toward understanding Machado\u2013Joseph disease. Prog Neurobiol. 2012;97:239\u201357.","journal-title":"Prog Neurobiol"},{"key":"1605_CR5","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41582-018-0051-6","volume":"14","author":"T Ashizawa","year":"2018","unstructured":"Ashizawa T, \u00d6z G, Paulson HL. Spinocerebellar ataxias: prospects and challenges for therapy development. Nat Rev Neurol. 2018;14:590\u2013605.","journal-title":"Nat Rev Neurol"},{"key":"1605_CR6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrn.2017.92","volume":"18","author":"HL Paulson","year":"2017","unstructured":"Paulson HL, Shakkottai VG, Clark HB, Orr HT. Polyglutamine spinocerebellar ataxias\u2014from genes to potential treatments. Nat Rev Neurosci. 2017;18:613\u201326.","journal-title":"Nat Rev Neurosci"},{"key":"1605_CR7","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s13311-019-00810-8","volume":"16","author":"S Naphade","year":"2019","unstructured":"Naphade S, Tshilenge KT, Ellerby LM. Modeling polyglutamine expansion diseases with induced pluripotent stem cells. Neurotherapeutics. 2019;16:979\u201398.","journal-title":"Neurotherapeutics"},{"key":"1605_CR8","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861\u201372.","journal-title":"Cell"},{"key":"1605_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nature10761","volume":"481","author":"DA Robinton","year":"2012","unstructured":"Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature. 2012;481:295\u2013305.","journal-title":"Nature"},{"key":"1605_CR10","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.stemcr.2017.01.022","volume":"8","author":"X Xu","year":"2017","unstructured":"Xu X, Tay Y, Sim B, Yoon SI, Huang Y, Ooi J, et al. Reversal of Phenotypic abnormalities by CRISPR\/Cas9-mediated gene correction in Huntington disease patient-derived induced pluripotent stem cells. Stem Cell Rep. 2017;8:619\u201333.","journal-title":"Stem Cell Rep"},{"key":"1605_CR11","doi-asserted-by":"crossref","unstructured":"He L, Chen Z, Peng L, Tang B, Jiang H. Human stem cell models of polyglutamine diseases: sources for disease models and cell therapy. Exp Neurol 2021;337:113573.","DOI":"10.1016\/j.expneurol.2020.113573"},{"key":"1605_CR12","doi-asserted-by":"crossref","unstructured":"Singh A, Kukreti R, Saso L, Kukreti S. Oxidative stress: a key modulator in neurodegenerative diseases. Molecules 2019;24:1583.","DOI":"10.3390\/molecules24081583"},{"key":"1605_CR13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00415-018-9076-4","volume":"266","author":"R Sullivan","year":"2019","unstructured":"Sullivan R, Yau WY, O\u2019Connor E, Houlden H. Spinocerebellar ataxia: an update. J Neurol. 2019;266:533\u201344.","journal-title":"J Neurol"},{"key":"1605_CR14","doi-asserted-by":"crossref","first-page":"2525967","DOI":"10.1155\/2017\/2525967","volume":"2017","author":"Z Liu","year":"2017","unstructured":"Liu Z, Zhou T, Ziegler AC, Dimitrion P, Zuo L. Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications. Oxid Med Cell Longev. 2017;2017:2525967.","journal-title":"Oxid Med Cell Longev"},{"key":"1605_CR15","first-page":"242","volume":"2","author":"S Chakrabarti","year":"2011","unstructured":"Chakrabarti S, Munshi S, Banerjee K, Thakurta IG, Sinha M, Bagh MB. Mitochondrial dysfunction during brain aging: role of oxidative stress and modulation by antioxidant supplementation. Aging Dis. 2011;2:242\u201356.","journal-title":"Aging Dis"},{"key":"1605_CR16","doi-asserted-by":"publisher","first-page":"2105607","DOI":"10.1155\/2019\/2105607","volume":"2019","author":"G Cenini","year":"2019","unstructured":"Cenini G, Lloret A, Cascella R. Oxidative stress in neurodegenerative diseases: from a mitochondrial point of view. Oxid Med Cell Longev. 2019;2019:2105607.","journal-title":"Oxid Med Cell Longev"},{"key":"1605_CR17","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/jnr.22011","volume":"87","author":"YC Yu","year":"2009","unstructured":"Yu YC, Kuo CL, Cheng WL, Liu CS, Hsieh M. Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado\u2013Joseph disease. J Neurosci Res. 2009;87:1884\u201391.","journal-title":"J Neurosci Res"},{"key":"1605_CR18","doi-asserted-by":"publisher","first-page":"7909380","DOI":"10.1155\/2016\/7909380","volume":"2016","author":"V Chiurchi\u00f9","year":"2016","unstructured":"Chiurchi\u00f9 V, Orlacchio A, Maccarrone M. Is modulation of oxidative stress an answer? The state of the art of redox therapeutic actions in neurodegenerative diseases. Oxid Med Cell Longev. 2016;2016:7909380.","journal-title":"Oxid Med Cell Longev"},{"key":"1605_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ab.2016.10.021","volume":"524","author":"D Tsikas","year":"2017","unstructured":"Tsikas D. Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: analytical and biological challenges. Anal Biochem. 2017;524:13\u201330.","journal-title":"Anal Biochem"},{"key":"1605_CR20","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.omtn.2019.12.012","volume":"19","author":"A Kotowska-Zimmer","year":"2020","unstructured":"Kotowska-Zimmer A, Ostrovska Y, Olejniczak M. Universal RNAi triggers for the specific inhibition of mutant Huntingtin, atrophin-1, ataxin-3, and ataxin-7 expression. Mol Ther Nucleic Acids. 2020;19:562\u201371.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1605_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.omtn.2017.04.005","volume":"7","author":"LR Moore","year":"2017","unstructured":"Moore LR, Rajpal G, Dillingham IT, Qutob M, Blumenstein KG, Gattis D, et al. Evaluation of antisense oligonucleotides targeting ATXN3 in SCA3 mouse models. Mol Ther Nucleic Acids. 2017;7:200\u201310.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1605_CR22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.omtn.2017.06.019","volume":"8","author":"LJA Toonen","year":"2017","unstructured":"Toonen LJA, Rigo F, van Attikum H, van Roon-Mom WMC. Antisense oligonucleotide-mediated removal of the polyglutamine repeat in spinocerebellar ataxia type 3 mice. Mol Ther Nucleic Acids. 2017;8:232\u201342.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1605_CR23","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nature22044","volume":"544","author":"DR Scoles","year":"2017","unstructured":"Scoles DR, Meera P, Schneider MD, Paul S, Dansithong W, Figueroa KP, et al. Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature. 2017;544:362\u20136.","journal-title":"Nature"},{"key":"1605_CR24","doi-asserted-by":"publisher","first-page":"104635","DOI":"10.1016\/j.nbd.2019.104635","volume":"134","author":"HS McLoughlin","year":"2020","unstructured":"McLoughlin HS, Moore LR, Paulson HL. Pathogenesis of SCA3 and implications for other polyglutamine diseases. Neurobiol Dis. 2020;134:104635.","journal-title":"Neurobiol Dis"},{"key":"1605_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.tig.2015.02.003","volume":"31","author":"GF Richard","year":"2015","unstructured":"Richard GF. Shortening trinucleotide repeats using highly specific endonucleases: a possible approach to gene therapy? Trends Genet. 2015;31:177\u201386.","journal-title":"Trends Genet"},{"key":"1605_CR26","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281\u2013308.","journal-title":"Nat Protoc"},{"key":"1605_CR27","doi-asserted-by":"publisher","first-page":"1258096","DOI":"10.1126\/science.1258096","volume":"346","author":"JA Doudna","year":"2014","unstructured":"Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346:1258096.","journal-title":"Science"},{"key":"1605_CR28","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","volume":"154","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell. 2013;154:1380\u20139.","journal-title":"Cell"},{"key":"1605_CR29","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1089\/scd.2017.0209","volume":"27","author":"S Ouyang","year":"2018","unstructured":"Ouyang S, Xie Y, Xiong Z, Yang Y, Xian Y, Ou Z, et al. CRISPR\/Cas9-targeted deletion of polyglutamine in spinocerebellar ataxia type 3-derived induced pluripotent stem cells. Stem Cells Dev. 2018;27:756\u201370.","journal-title":"Stem Cells Dev"},{"key":"1605_CR30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.stem.2012.04.026","volume":"11","author":"MC An","year":"2012","unstructured":"An MC, Zhang N, Scott G, Montoro D, Wittkop T, Mooney S, et al. Genetic correction of Huntington\u2019s disease phenotypes in induced pluripotent stem cells. Cell Stem Cell. 2012;11:253\u201363.","journal-title":"Cell Stem Cell"},{"key":"1605_CR31","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nbt.2675","volume":"31","author":"P Mali","year":"2013","unstructured":"Mali P, Aach J, Stranges PB, Esvelt KM, Moosburner M, Kosuri S, et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol. 2013;31:833\u20138.","journal-title":"Nat Biotechnol"},{"key":"1605_CR32","doi-asserted-by":"publisher","first-page":"eaap9004","DOI":"10.1126\/sciadv.aap9004","volume":"4","author":"C Long","year":"2018","unstructured":"Long C, Li H, Tiburcy M, Rodriguez-Caycedo C, Kyrychenko V, Zhou H, et al. Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing. Sci Adv. 2018;4:eaap9004.","journal-title":"Sci Adv"},{"key":"1605_CR33","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.stemcr.2017.02.019","volume":"8","author":"A Bhinge","year":"2017","unstructured":"Bhinge A, Namboori SC, Zhang X, VanDongen AMJ, Stanton LW. Genetic correction of SOD1 mutant iPSCs reveals ERK and JNK activated AP1 as a driver of neurodegeneration in amyotrophic lateral sclerosis. Stem Cell Rep. 2017;8:856\u201369.","journal-title":"Stem Cell Rep"},{"key":"1605_CR34","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1172\/JCI92087","volume":"127","author":"S Yang","year":"2017","unstructured":"Yang S, Chang R, Yang H, Zhao T, Hong Y, Kong HE, et al. CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington\u2019s disease. J Clin Investig. 2017;127:2719\u201324.","journal-title":"J Clin Investig"},{"key":"1605_CR35","doi-asserted-by":"publisher","first-page":"101555","DOI":"10.1016\/j.scr.2019.101555","volume":"40","author":"L He","year":"2019","unstructured":"He L, Ye W, Chen Z, Wang C, Zhao H, Li S, et al. Generation of an induced pluripotent stem cell line (XHCSUi001-A) from urine cells of a patient with spinocerebellar ataxia type 3. Stem Cell Res. 2019;40:101555.","journal-title":"Stem Cell Res"},{"key":"1605_CR36","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.1016\/j.scr.2021.102289","volume":"53","author":"L He","year":"2021","unstructured":"He L, Han X, Zhao H, Li S, Chen Z, Wang C, et al. Generation of spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cell line (CSUXHi005-A) from human urine epithelial cells. Stem Cell Res. 2021;53:102289.","journal-title":"Stem Cell Res"},{"key":"1605_CR37","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nmeth.2812","volume":"11","author":"F Heigwer","year":"2014","unstructured":"Heigwer F, Kerr G, Boutros M. E-CRISP: fast CRISPR target site identification. Nat Methods. 2014;11:122\u20133.","journal-title":"Nat Methods"},{"key":"1605_CR38","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1093\/bioinformatics\/btu354","volume":"30","author":"A O\u2019Brien","year":"2014","unstructured":"O\u2019Brien A, Bailey TL. GT-Scan: identifying unique genomic targets. Bioinformatics. 2014;30:2673\u20135.","journal-title":"Bioinformatics"},{"key":"1605_CR39","doi-asserted-by":"publisher","first-page":"101816","DOI":"10.1016\/j.scr.2020.101816","volume":"45","author":"L He","year":"2020","unstructured":"He L, Zhao H, Li S, Han X, Chen Z, Wang C, et al. Generation of induced pluripotent stem cell line (CSUXHi002-A) from a patient with spinocerebellar ataxia type 1. Stem Cell Res. 2020;45:101816.","journal-title":"Stem Cell Res"},{"key":"1605_CR40","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1038\/nprot.2012.116","volume":"7","author":"Y Shi","year":"2012","unstructured":"Shi Y, Kirwan P, Livesey FJ. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat Protoc. 2012;7:1836\u201346.","journal-title":"Nat Protoc"},{"key":"1605_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.203","volume":"6","author":"J Liu","year":"2016","unstructured":"Liu J, Gao C, Chen W, Ma W, Li X, Shi Y, et al. CRISPR\/Cas9 facilitates investigation of neural circuit disease using human iPSCs: mechanism of epilepsy caused by an SCN1A loss-of-function mutation. Transl Psychiatry. 2016;6:e703.","journal-title":"Transl Psychiatry"},{"key":"1605_CR42","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature10671","volume":"480","author":"P Koch","year":"2011","unstructured":"Koch P, Breuer P, Peitz M, Jungverdorben J, Kesavan J, Poppe D, et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado\u2013Joseph disease. Nature. 2011;480:543\u20136.","journal-title":"Nature"},{"key":"1605_CR43","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s12035-019-01734-2","volume":"57","author":"J Hamilton","year":"2020","unstructured":"Hamilton J, Brustovetsky T, Sridhar A, Pan Y, Cummins TR, Meyer JS, et al. Energy metabolism and mitochondrial superoxide anion production in pre-symptomatic striatal neurons derived from human-induced pluripotent stem cells expressing mutant Huntingtin. Mol Neurobiol. 2020;57:668\u201384.","journal-title":"Mol Neurobiol"},{"key":"1605_CR44","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/nn.2638","volume":"13","author":"K Muguruma","year":"2010","unstructured":"Muguruma K, Nishiyama A, Ono Y, Miyawaki H, Mizuhara E, Hori S, et al. Ontogeny-recapitulating generation and tissue integration of ES cell-derived Purkinje cells. Nat Neurosci. 2010;13:1171\u201380.","journal-title":"Nat Neurosci"},{"key":"1605_CR45","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.celrep.2014.12.051","volume":"10","author":"K Muguruma","year":"2015","unstructured":"Muguruma K, Nishiyama A, Kawakami H, Hashimoto K, Sasai Y. Self-organization of polarized cerebellar tissue in 3D culture of human pluripotent stem cells. Cell Rep. 2015;10:537\u201350.","journal-title":"Cell Rep"},{"key":"1605_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/srep09232","volume":"5","author":"S Wang","year":"2015","unstructured":"Wang S, Wang B, Pan N, Fu L, Wang C, Song G, et al. Differentiation of human induced pluripotent stem cells to mature functional Purkinje neurons. Sci Rep. 2015;5:9232.","journal-title":"Sci Rep"},{"key":"1605_CR47","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1038\/s41380-018-0018-4","volume":"23","author":"M Sundberg","year":"2018","unstructured":"Sundberg M, Tochitsky I, Buchholz DE, Winden K, Kujala V, Kapur K, et al. Purkinje cells derived from TSC patients display hypoexcitability and synaptic deficits associated with reduced FMRP levels and reversed by rapamycin. Mol Psychiatry. 2018;23:2167\u201383.","journal-title":"Mol Psychiatry"},{"key":"1605_CR48","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s13311-019-00798-1","volume":"16","author":"JD Da Silva","year":"2019","unstructured":"Da Silva JD, Teixeira-Castro A, Maciel P. From pathogenesis to novel therapeutics for spinocerebellar ataxia type 3: evading potholes on the way to translation. Neurotherapeutics. 2019;16:1009\u201331.","journal-title":"Neurotherapeutics"},{"key":"1605_CR49","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1038\/mt.2013.144","volume":"21","author":"C Costa Mdo","year":"2013","unstructured":"Costa Mdo C, Luna-Cancalon K, Fischer S, Ashraf NS, Ouyang M, Dharia RM, et al. Toward RNAi therapy for the polyglutamine disease Machado\u2013Joseph disease. Mol Ther. 2013;21:1898\u2013908.","journal-title":"Mol Ther"},{"key":"1605_CR50","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.nbd.2013.04.019","volume":"58","author":"MM Evers","year":"2013","unstructured":"Evers MM, Tran HD, Zalachoras I, Pepers BA, Meijer OC, den Dunnen JT, et al. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon. Neurobiol Dis. 2013;58:49\u201356.","journal-title":"Neurobiol Dis"},{"key":"1605_CR51","doi-asserted-by":"crossref","unstructured":"McIntosh CS, Aung-Htut MT, Fletcher S, Wilton SD. Removal of the polyglutamine repeat of ataxin-3 by redirecting pre-mRNA processing. Int J Mol Sci 2019;20.","DOI":"10.3390\/ijms20215434"},{"key":"1605_CR52","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/ana.25264","volume":"84","author":"HS McLoughlin","year":"2018","unstructured":"McLoughlin HS, Moore LR, Chopra R, Komlo R, McKenzie M, Blumenstein KG, et al. Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice. Ann Neurol. 2018;84:64\u201377.","journal-title":"Ann Neurol"},{"key":"1605_CR53","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/brain\/awz328","volume":"143","author":"AC Silva","year":"2020","unstructured":"Silva AC, Lobo DD, Martins IM, Lopes SM, Henriques C, Duarte SP, et al. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders. Brain. 2020;143:407\u201329.","journal-title":"Brain"},{"key":"1605_CR54","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s13311-018-00696-y","volume":"16","author":"RAM Buijsen","year":"2019","unstructured":"Buijsen RAM, Toonen LJA, Gardiner SL, van Roon-Mom WMC. Genetics, mechanisms, and therapeutic progress in polyglutamine spinocerebellar ataxias. Neurotherapeutics. 2019;16:263\u201386.","journal-title":"Neurotherapeutics"},{"key":"1605_CR55","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/med.21425","volume":"37","author":"S Esteves","year":"2017","unstructured":"Esteves S, Duarte-Silva S, Maciel P. Discovery of therapeutic approaches for polyglutamine diseases: a summary of recent efforts. Med Res Rev. 2017;37:860\u2013906.","journal-title":"Med Res Rev"},{"key":"1605_CR56","doi-asserted-by":"crossref","unstructured":"Afonso-Reis R, Afonso IT, N\u00f3brega C. Current status of gene therapy research in polyglutamine spinocerebellar ataxias. Int J Mol Sci 2021;22.","DOI":"10.3390\/ijms22084249"},{"key":"1605_CR57","first-page":"4566","volume":"25","author":"JW Shin","year":"2016","unstructured":"Shin JW, Kim KH, Chao MJ, Atwal RS, Gillis T, MacDonald ME, et al. Permanent inactivation of Huntington\u2019s disease mutation by personalized allele-specific CRISPR\/Cas9. Hum Mol Genet. 2016;25:4566\u201376.","journal-title":"Hum Mol Genet"},{"key":"1605_CR58","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","volume":"25","author":"AM Monteys","year":"2017","unstructured":"Monteys AM, Ebanks SA, Keiser MS, Davidson BL. CRISPR\/Cas9 editing of the mutant Huntingtin allele in vitro and in vivo. Mol Ther. 2017;25:12\u201323.","journal-title":"Mol Ther"},{"key":"1605_CR59","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.omtn.2019.07.009","volume":"17","author":"FK Ekman","year":"2019","unstructured":"Ekman FK, Ojala DS, Adil MM, Lopez PA, Schaffer DV, Gaj T. CRISPR-Cas9-mediated genome editing increases lifespan and improves motor deficits in a Huntington\u2019s disease mouse model. Mol Ther Nucleic Acids. 2019;17:829\u201339.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1605_CR60","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3389\/fnmol.2017.00196","volume":"10","author":"JY Hsu","year":"2017","unstructured":"Hsu JY, Jhang YL, Cheng PH, Chang YF, Mao SH, Yang HI, et al. The truncated C-terminal fragment of mutant ATXN3 disrupts mitochondria dynamics in spinocerebellar ataxia type 3 models. Front Mol Neurosci. 2017;10:196.","journal-title":"Front Mol Neurosci"},{"key":"1605_CR61","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1093\/brain\/aws177","volume":"135","author":"AT Sim\u00f5es","year":"2012","unstructured":"Sim\u00f5es AT, Gon\u00e7alves N, Koeppen A, D\u00e9glon N, K\u00fcgler S, Duarte CB, et al. Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado\u2013Joseph disease. Brain. 2012;135:2428\u201339.","journal-title":"Brain"},{"key":"1605_CR62","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2174\/1381612822666161227121912","volume":"23","author":"CA Matos","year":"2017","unstructured":"Matos CA, Almeida LP, Nobrega C. Proteolytic cleavage of polyglutamine disease-causing proteins: revisiting the toxic fragment hypothesis. Curr Pharm Des. 2017;23:753\u201375.","journal-title":"Curr Pharm Des"},{"key":"1605_CR63","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.omtn.2017.04.018","volume":"7","author":"F Yang","year":"2017","unstructured":"Yang F, Liu C, Chen D, Tu M, Xie H, Sun H, et al. CRISPR\/Cas9-loxP-mediated gene editing as a novel site-specific genetic manipulation tool. Mol Ther Nucleic Acids. 2017;7:378\u201386.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1605_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89312-2","volume":"11","author":"PP Li","year":"2021","unstructured":"Li PP, Margolis RL. Use of single guided Cas9 nickase to facilitate precise and efficient genome editing in human iPSCs. Sci Rep. 2021;11:9865.","journal-title":"Sci Rep"},{"key":"1605_CR65","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12311-017-0913-2","volume":"17","author":"LM Watson","year":"2018","unstructured":"Watson LM, Wong MMK, Vowles J, Cowley SA, Becker EBE. A simplified method for generating Purkinje cells from human-induced pluripotent stem cells. Cerebellum. 2018;17:419\u201327.","journal-title":"Cerebellum"},{"key":"1605_CR66","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.celrep.2016.10.026","volume":"17","author":"Y Ishida","year":"2016","unstructured":"Ishida Y, Kawakami H, Kitajima H, Nishiyama A, Sasai Y, Inoue H, et al. Vulnerability of Purkinje cells generated from spinocerebellar ataxia type 6 patient-derived iPSCs. Cell Rep. 2016;17:1482\u201390.","journal-title":"Cell Rep"},{"key":"1605_CR67","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/hmg\/ddp482","volume":"19","author":"CP Reina","year":"2010","unstructured":"Reina CP, Zhong X, Pittman RN. Proteotoxic stress increases nuclear localization of ataxin-3. Hum Mol Genet. 2010;19:235\u201349.","journal-title":"Hum Mol Genet"},{"key":"1605_CR68","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.nbd.2007.06.005","volume":"27","author":"VF Colomer Gould","year":"2007","unstructured":"Colomer Gould VF, Goti D, Pearce D, Gonzalez GA, Gao H, Bermudez de Leon M, et al. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice. Neurobiol Dis. 2007;27:362\u20139.","journal-title":"Neurobiol Dis"},{"key":"1605_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05320-3","volume":"9","author":"S Koyuncu","year":"2018","unstructured":"Koyuncu S, Saez I, Lee HJ, Gutierrez-Garcia R, Pokrzywa W, Fatima A, et al. The ubiquitin ligase UBR5 suppresses proteostasis collapse in pluripotent stem cells from Huntington\u2019s disease patients. Nat Commun. 2018;9:2886.","journal-title":"Nat Commun"},{"key":"1605_CR70","doi-asserted-by":"publisher","first-page":"101504","DOI":"10.1016\/j.scr.2019.101504","volume":"39","author":"LR Moore","year":"2019","unstructured":"Moore LR, Keller L, Bushart DD, Delatorre RG, Li D, McLoughlin HS, et al. Antisense oligonucleotide therapy rescues aggresome formation in a novel spinocerebellar ataxia type 3 human embryonic stem cell line. Stem Cell Res. 2019;39:101504.","journal-title":"Stem Cell Res"},{"key":"1605_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-37774-2","volume":"9","author":"CY Chuang","year":"2019","unstructured":"Chuang CY, Yang CC, Soong BW, Yu CY, Chen SH, Huang HP, et al. Modeling spinocerebellar ataxias 2 and 3 with iPSCs reveals a role for glutamate in disease pathology. Sci Rep. 2019;9:1166.","journal-title":"Sci Rep"},{"key":"1605_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/srep30436","volume":"6","author":"JC Chang","year":"2016","unstructured":"Chang JC, Wu SL, Hoel F, Cheng YS, Liu KH, Hsieh M, et al. Far-infrared radiation protects viability in a cell model of Spinocerebellar Ataxia by preventing polyQ protein accumulation and improving mitochondrial function. Sci Rep. 2016;6:30436.","journal-title":"Sci Rep"},{"key":"1605_CR73","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3389\/fneur.2017.00485","volume":"8","author":"AM de Assis","year":"2017","unstructured":"de Assis AM, Saute J, Longoni A, Haas CB, Torrez VR, Brochier AW, et al. Peripheral oxidative stress biomarkers in spinocerebellar ataxia type 3\/Machado\u2013Joseph disease. Front Neurol. 2017;8:485.","journal-title":"Front Neurol"},{"key":"1605_CR74","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s12035-018-1069-x","volume":"56","author":"M Raposo","year":"2019","unstructured":"Raposo M, Ramos A, Santos C, Kazachkova N, Teixeira B, Bettencourt C, et al. Accumulation of mitochondrial DNA common deletion since the preataxic stage of Machado\u2013Joseph disease. Mol Neurobiol. 2019;56:119\u201324.","journal-title":"Mol Neurobiol"},{"key":"1605_CR75","doi-asserted-by":"crossref","unstructured":"Angeloni C, Gatti M, Prata C, Hrelia S, Maraldi T. Role of mesenchymal stem cells in counteracting oxidative stress-related neurodegeneration. Int J Mol Sci 2020;21.","DOI":"10.3390\/ijms21093299"},{"key":"1605_CR76","doi-asserted-by":"publisher","first-page":"621996","DOI":"10.3389\/fnins.2021.621996","volume":"15","author":"EN Minakawa","year":"2021","unstructured":"Minakawa EN, Nagai Y. Protein aggregation inhibitors as disease-modifying therapies for polyglutamine diseases. Front Neurosci. 2021;15:621996.","journal-title":"Front Neurosci"},{"key":"1605_CR77","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.mrgentox.2013.06.023","volume":"757","author":"LS Pacheco","year":"2013","unstructured":"Pacheco LS, da Silveira AF, Trott A, Houenou LJ, Algarve TD, Bell\u00f3 C, et al. Association between Machado\u2013Joseph disease and oxidative stress biomarkers. Mutat Res. 2013;757:99\u2013103.","journal-title":"Mutat Res"},{"key":"1605_CR78","first-page":"8130481","volume":"2019","author":"IC Chen","year":"2019","unstructured":"Chen IC, Chang KH, Chen YJ, Chen YC, Lee-Chen GJ, Chen CM. Pueraria lobata and daidzein reduce cytotoxicity by enhancing ubiquitin-proteasome system function in SCA3-iPSC-derived neurons. Oxid Med Cell Longev. 2019;2019:8130481.","journal-title":"Oxid Med Cell Longev"},{"key":"1605_CR79","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/mds.27292","volume":"33","author":"S Duarte-Silva","year":"2018","unstructured":"Duarte-Silva S, Neves-Carvalho A, Soares-Cunha C, Silva JM, Teixeira-Castro A, Vieira R, et al. Neuroprotective effects of creatine in the CMVMJD135 mouse model of spinocerebellar ataxia type 3. Mov Disord. 2018;33:815\u201326.","journal-title":"Mov Disord"},{"key":"1605_CR80","doi-asserted-by":"publisher","first-page":"8168","DOI":"10.1007\/s12035-019-01643-4","volume":"56","author":"K Wiatr","year":"2019","unstructured":"Wiatr K, Piasecki P, Marczak \u0141, Wojciechowski P, Kurkowiak M, P\u0142oski R, et al. Altered levels of proteins and phosphoproteins, in the absence of early causative transcriptional changes, shape the molecular pathogenesis in the brain of young presymptomatic Ki91 SCA3\/MJD mouse. Mol Neurobiol. 2019;56:8168\u2013202.","journal-title":"Mol Neurobiol"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01605-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01605-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01605-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T14:21:52Z","timestamp":1725805312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01605-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1605"],"URL":"https:\/\/doi.org\/10.1038\/s41398-021-01605-2","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,17]]},"assertion":[{"value":"4 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"479"}}